✦ LIBER ✦

656 - A phase III trial comparing vorozole (RIVIZOR™) versus aminoglutethimlde in the treatment of advanced postmenopausal breast cancer

✍ Scribed by N.-O. Bengtsson; C. Focan; A. Gudgeon; H.J. Illiger; D. Khayat; R. Murray; J.W.R. Nortier; J. Waxman; C. Xielinski

Book ID: 117664903
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 266 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)85234-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase III trial of oral high-dose medr

A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer

✍ Masaru Izuo; Minoru Yoshida; Takeshi Tominaga; Osahiko Abe; Koji Enomoto; Yasuo 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB 👁 2 views

0-72. Rivizor® versus aminoglutethimide

0-72. Rivizor® versus aminoglutethimide (AG) in the second-line endocrine treatment of postmenopausal patients with advanced breast cancer (ABC) following tamoxifen failure

✍ S.J. Houston 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 300 KB

Results of the CONFIRM Phase III Trial C

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250mg With Fulvestrant 500mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

✍ Jordan, V.C. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

“Classical” CMF versus a 3-weekly intrav

“Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

✍ E. Engelsman; J.C.M. Klijn; R.D. Rubens; J. Wildiers; L.V.A.M. Beex; M.A. Nooij; 📂 Article 📅 1991 🏛 Elsevier Science ⚖ 543 KB

A prospective randomized trial of doxoru

A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer

✍ Massimo Lopez; Alma Contegiacomo; Patrizia Vici; Concetta Dello Ioio; Luigi Di L 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB 👁 2 views

Seventy-six patients with advanced breast cancer were entered into the current study. They were randomized to receive either idarubicin (IDA) 45 mg/m2 orally or doxorubicin (DX) 75 mg/m2 intravenously (IV), both drugs being administered every 3 weeks. Among 37 evaluable patients who received DX trea

Phase III randomized trial of sunitinib

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

✍ Carlos H. Barrios; Mei-Ching Liu; Soo Chin Lee; Laurence Vanlemmens; Jean-Marc F 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 289 KB